SAREPTA THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: SAREPTA THERAPEUTICS INC. - COMMON STOCK

21 Jun 2024 08:45:14 By NetDania Notify

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Jan 2023 17:20:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues

09 Jan 2023 12:28:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Dec 2022 16:58:49 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Nov 2022 17:00:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

28 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference

23 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments

02 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Oct 2022 17:00:31 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results

26 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022

07 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Sep 2022 17:15:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

29 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027

14 Sep 2022 06:00:25 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027

12 Sep 2022 15:41:31 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year

07 Sep 2022 07:30:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 07:45:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

06 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Aug 2022 16:59:49 By Nasdaq GlobeNewswire